SOURCE: SciClone Pharmaceuticals, Inc.

October 30, 2007 06:30 ET

SciClone Pharmaceuticals to Report Third Quarter 2007 Results on November 13, 2007

FOSTER CITY, CA--(Marketwire - October 30, 2007) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report third quarter 2007 results and host a conference call on Tuesday, November 13, 2007.

The conference call will contain forward-looking statements. Financial and statistical information to be discussed on the call will be posted on the Investor Relations section of SciClone's website at prior to the commencement of the conference call.

DATE:       Tuesday, November 13, 2007
TIME:       11:00 a.m. ET (8:00 a.m. PT)
WEBCAST:    Live call and replay accessible at
LIVE CALL:  888-205-6439 (U.S./Canada)
            913-312-1436 (International)
REPLAY:     888-203-1112 (U.S./Canada)
            719-457-0820 (International)
            Passcode:  8868427
            (Replay available from 2:00 p.m. ET on November 13, 2007
            through 12:00 a.m. ET on December 13, 2007)

About SciClone

SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN® (thymalfasin) is currently being evaluated in late-stage clinical trials for the treatment of malignant melanoma and hepatitis C virus. ZADAXIN is approved for sale in select markets internationally, most notably China where SciClone has an established sales and marketing operation. A key part of SciClone's strategy is to leverage its advantage and broaden its portfolio in the rapidly growing Chinese market by in-licensing or acquiring the marketing rights to other products, such as DC Bead™. For the U.S. market, SciClone's clinical-stage drug development candidates are RP101 for the treatment of pancreatic cancer and SCV-07 for the treatment of hepatitis C virus. For more information about SciClone, visit

Contact Information

  • Corporate Contact:
    Richard Waldron
    Executive Vice President & Chief Financial Officer
    SciClone Pharmaceuticals, Inc.
    (650) 358-3437